E Bernichon1, E Daguenet2, C Molla3, J Cornillon4, C Lejeune5, F Casteillo6, D Guyotat7, E Tavernier8. 1. Department of Clinical Hematology, institut de cancérologie Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France. Electronic address: emilie.bernichon@gmail.com. 2. Department of Clinical Hematology, institut de cancérologie Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France. Electronic address: elisabeth.daguenet@icloire.fr. 3. Department of Clinical Hematology, institut de cancérologie Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France. Electronic address: mollacoraline18@gmail.com. 4. Department of Clinical Hematology, institut de cancérologie Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France. Electronic address: jerome.cornillon@icloire.fr. 5. Department of Clinical Hematology, institut de cancérologie Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France. Electronic address: caroline.lejeune@icloire.fr. 6. Department of Pathology, University Hospital, 42000 Saint-Étienne, France. Electronic address: francois.casteillo@chu-st-etienne.fr. 7. Department of Clinical Hematology, institut de cancérologie Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France. Electronic address: denis.guyotat@icloire.fr. 8. Department of Clinical Hematology, institut de cancérologie Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France. Electronic address: emmanuelle.tarvernier@icloire.fr.
Abstract
AIM: SOS/VOD is a relevant clinical syndrome that usually appears early after hematopoietic stem cell transplantation. The purpose of this article was to report a case series of SOS/VOD in non-susceptible patients and draw physicians' attention to the plausible relationship between liver injury and oxaliplatin-based chemotherapy, preceding autologous transplantation. METHODS: In this study, we report a case series of SOS/VOD in 4 lymphoma patients following autologous transplantation. The data were collected between July 2013 and November 2015 by analyzing patient's characteristics and outcomes. RESULTS: We noticed 4 severe cases of SOS with unusual presentations in patients who did exhibit few classical risk factors. These patients received R-DHAO before transplantation. CONCLUSIONS: Physicians need to be aware that oxaliplatin-based regimen could contribute to SOS/VOD complications in hematological patients.
AIM: SOS/VOD is a relevant clinical syndrome that usually appears early after hematopoietic stem cell transplantation. The purpose of this article was to report a case series of SOS/VOD in non-susceptible patients and draw physicians' attention to the plausible relationship between liver injury and oxaliplatin-based chemotherapy, preceding autologous transplantation. METHODS: In this study, we report a case series of SOS/VOD in 4 lymphomapatients following autologous transplantation. The data were collected between July 2013 and November 2015 by analyzing patient's characteristics and outcomes. RESULTS: We noticed 4 severe cases of SOS with unusual presentations in patients who did exhibit few classical risk factors. These patients received R-DHAO before transplantation. CONCLUSIONS: Physicians need to be aware that oxaliplatin-based regimen could contribute to SOS/VOD complications in hematological patients.